BeyondSpring is a clinical-stage biopharmaceutical company developing cancer therapies through two primary platforms: Plinabulin, a lead asset demonstrating survival benefits in lung cancer trials, and a Targeted Protein Degradation platform acquired through SEED Therapeutics that uses molecular glue technology to degrade undruggable proteins. The company's development programs focus on the U.S. and China markets, with clinical and regulatory partnerships spanning major contract research organizations and partnerships with pharmaceutical companies including Eli Lilly and Eisai. BeyondSpring has not yet generated product sales revenue but has received upfront payments from partnership agreements with a subsidiary commercializing Plinabulin in Greater China; the company sustains operations through equity financing and relies on milestone payments and potential royalties from its partnerships to advance product candidates toward regulatory approval and commercial launch.